ArisGlobal Signs Agreement to Acquire Amplexor Life Sciences
ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere® has announced the acquisition of Amplexor Life Sciences (LS), a global provider of regulatory, quality, and safety software solutions, serving and trusted by pharmaceutical, biotechnology, and medical device companies.
The integration of the regulatory product lines will bring a distinct set of benefits to customers. LifeSphere users are now gaining access to enhanced publishing and labeling capabilities; in addition to a robust Quality Management System (QMS) from Amplexor LS. Amplexor LS’s regulatory customers can now connect to even wider functionality through ArisGlobal’s market leading LifeSphere platform including access to state-of-the-art Intelligent Content management, Safety, Medical Affairs and Clinical solutions. This combined product ecosystem provides a new opportunity for life sciences companies, bringing together best in breed solutions to form a cohesive solution serving customers’ regulatory needs. It also represents many years of industry expertise, software innovation, and customer excellence from ArisGlobal and Amplexor Life Sciences. This move will accelerate both companies’ roadmaps and increase efficiency in bringing new therapies to the market.
“For many years, ArisGlobal has been focused on building a regulatory platform that provides a market-leading, comprehensive set of products and streamlines processes supporting collaboration across distributed teams while adhering to extensive and evolving global regulatory requirements,” shares Mike Gordon, chief executive officer at ArisGlobal. “By combining our core functionalities, we are elevating our end-to-end Regulatory capabilities to enhance our customers’ journey.”
“Amplexor Life Sciences has always sought to provide their customers with operational excellence in global compliance, and this new chapter of our products within the LifeSphere Regulatory platform will continue to do that,” states Elvis Paćelat, Executive Vice President at Amplexor LS. “We are excited to join forces with ArisGlobal, who has been an innovator in the life sciences space for several decades, to provide the market with a full scope of products designed to make regulatory processes a connected, cloud-based, and compliant experience.”
“The vision and objectives of ArisGlobal and Amplexor LS are aligned,” shares Jim Hilferty, AVP and Head of Regulatory at ArisGlobal. “We’re confident that bringing our organizations together will serve as a catalyst for innovation to benefit life sciences, and allow us to deliver the most intelligent, connected, and comprehensive platform available to the regulatory community.”
Both companies have been supporting R&D processes through technology for decades, with offices throughout Europe, United States, India, and the APAC region. The integration is subject to customary government approvals that are expected to be completed in the next 60 days. Further information will be made available on the combined solution.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more